UNICA IRIS Institutional Research Information System

CHESSA, LUCHINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 220.760
NA - Nord America 17.142
AS - Asia 7.082
SA - Sud America 1.432
Continente sconosciuto - Info sul continente non disponibili 690
AF - Africa 249
OC - Oceania 40
Totale 247.395
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 215.330
US - Stati Uniti d'America 16.657
SG - Singapore 2.777
CN - Cina 2.170
NL - Olanda 1.184
BR - Brasile 1.092
SE - Svezia 906
UA - Ucraina 747
VN - Vietnam 683
DE - Germania 595
GB - Regno Unito 552
FI - Finlandia 518
FR - Francia 391
HK - Hong Kong 331
CA - Canada 265
IN - India 191
BD - Bangladesh 157
KR - Corea 140
AR - Argentina 118
RU - Federazione Russa 84
AT - Austria 79
MX - Messico 77
IQ - Iraq 75
ZA - Sudafrica 72
JP - Giappone 67
ID - Indonesia 59
TR - Turchia 58
PL - Polonia 52
CO - Colombia 50
IE - Irlanda 48
ES - Italia 47
MA - Marocco 47
EC - Ecuador 46
PK - Pakistan 45
VE - Venezuela 37
AU - Australia 36
LT - Lituania 35
CL - Cile 33
PH - Filippine 33
SA - Arabia Saudita 33
JM - Giamaica 28
UZ - Uzbekistan 28
MY - Malesia 27
IL - Israele 26
BE - Belgio 24
KE - Kenya 24
CZ - Repubblica Ceca 23
CR - Costa Rica 22
EG - Egitto 22
PY - Paraguay 22
IR - Iran 20
TN - Tunisia 19
AZ - Azerbaigian 17
GT - Guatemala 17
TW - Taiwan 16
CH - Svizzera 15
JO - Giordania 15
HN - Honduras 14
KZ - Kazakistan 14
DK - Danimarca 13
PE - Perù 13
TT - Trinidad e Tobago 13
AE - Emirati Arabi Uniti 12
RO - Romania 12
TH - Thailandia 12
UY - Uruguay 12
SV - El Salvador 11
DZ - Algeria 10
HR - Croazia 10
LB - Libano 10
PA - Panama 10
SC - Seychelles 10
KG - Kirghizistan 9
MD - Moldavia 9
NI - Nicaragua 9
OM - Oman 9
AO - Angola 8
PT - Portogallo 8
RS - Serbia 8
AL - Albania 7
BG - Bulgaria 7
BO - Bolivia 7
EE - Estonia 7
GR - Grecia 7
LV - Lettonia 7
SY - Repubblica araba siriana 7
CW - ???statistics.table.value.countryCode.CW??? 6
KW - Kuwait 6
BA - Bosnia-Erzegovina 5
BY - Bielorussia 5
HU - Ungheria 5
MK - Macedonia 5
NP - Nepal 5
PR - Porto Rico 5
BH - Bahrain 4
CG - Congo 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
MU - Mauritius 4
NO - Norvegia 4
Totale 246.633
Salva come PNG Salva come JPEG
Città #
Cagliari 208.343
Uta 5.009
Ashburn 2.548
Singapore 1.305
Dallas 1.217
San Jose 1.192
Amsterdam 1.097
Fairfield 915
Woodbridge 783
Chandler 736
Boardman 685
Houston 613
Nyköping 520
Ann Arbor 408
Jacksonville 397
Beijing 390
Council Bluffs 369
Seattle 364
Wilmington 356
Helsinki 354
Los Angeles 340
Cambridge 295
Hong Kong 295
New York 274
Santa Clara 270
Ho Chi Minh City 212
Boston 211
Rome 206
Lauterbourg 203
Hefei 196
Dearborn 193
Munich 178
São Paulo 175
Shanghai 162
The Dalles 152
Nanjing 150
Milan 140
Buffalo 129
Hanoi 125
Seoul 124
Toronto 93
San Diego 84
Chicago 80
Frankfurt am Main 79
Dong Ket 78
Orem 76
Redwood City 73
London 71
Columbus 66
Guangzhou 64
Montreal 61
Atlanta 57
Mansfield 57
Phoenix 56
Princeton 55
Nuremberg 54
Nanchang 52
Tokyo 52
Tianjin 48
Turku 48
Vienna 47
Redondo Beach 46
San Francisco 44
Brooklyn 42
Denver 42
Warsaw 41
Jiaxing 40
Changsha 39
Oxford 38
Shenyang 38
Hebei 37
Norwalk 37
Washington 37
Paris 36
Chennai 33
Dublin 33
Rio de Janeiro 33
Johannesburg 32
Stockholm 31
Da Nang 30
Baghdad 29
Casablanca 29
Manchester 28
Sassari 27
Naples 26
Haiphong 24
Tashkent 24
Dhaka 23
Orange 23
Verona 23
Belo Horizonte 22
Mexico City 22
Mountain View 22
Nottingham 22
San Mateo 22
Vilnius 22
Birmingham 21
Nairobi 21
Düsseldorf 20
Queens 20
Totale 234.161
Salva come PNG Salva come JPEG
Nome #
Comparing the responses of countries and National Health Systems to the COVID-19 pandemic: a critical analysis with a case-report series 20.862
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis 4.592
Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma 3.384
Gastrointestinal Coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management 3.323
HLA-G is highly expressed by plasma cells infiltrating hepatic tissue of patients affected by autoimmune hepatitis 3.157
Killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis: a possible pathogenetic role ? 3.152
Altered profile of salivary proteins in patients with Autoimmune Hepatitis 2.991
Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible? 2.957
Role of interferon lambda 4 and ALT levels in optimising treatment of HCV for patients with low-stage fibrosis 2.851
Impact of direct-acting antiviral drugs for chronic hepatitis C on mood: Preliminary results from a longitudinal study 2.762
Impact of natural killer (NK) cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients 2.746
IMPACT OF KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTORS ON PROGRESSION OF HEPATOCELLULAR CARCINOMA 2.662
Hippocampal axis dysfunction evaluation by Rey-Osterrieth Complex figure test (RCFT) should be included in minimal hepatic encephalopathy (MHE) assessment 2.654
Combination of IFNL4 polymorphisms and ALT reduction at 4 week of treatment with PEG IFN and Ribavirin is a new selection tool to optimize antiviral treatment allocation in HCV patients with low stage fibrosis 2.559
Behavior of bone mass in long-term HAART patients 2.540
Association of chronic hepatitis C with recurrent brief depression 2.484
FATTORI IMPLICATI NELLA STORIA NATURALE DELL'INFEZIONE DA VIRUS DELTA:IL RUOLO DEGLI INTERFERONI 2.463
Role of natural killercells receptors on the development and progression of hepatocellularcarcinoma 2.431
Role of HLA-G in autmoimmune hepatitis 2.341
INFLUENZA DEI POLIMORFISMI DELL’INTERFERONE LAMBDA NELLA STORIA NATURALE DELLA INFEZIONE CRONICA DA HBV: COINCIDENZA O REALTÀ? 2.320
Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis 2.241
Dynamics of TT virus infection in a cohort of HCV-infected patients achieving sustained virologic responce after treatment with direct-acting antivirals 2.205
Safety and efficacy of direct-acting antivirals in transfusion-dependent thalassemic patients with chronic hepatitis C 2.182
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience 2.053
Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in patients with chronic HCV infection treated with direct antiviral agents 2.036
A multivariate approach for the brain impairment in patients with liver cirrhosi 2.022
La neopterina uraria come marker di attività immunologica nelle malattie infiammatorie croniche dell’intestino 2.012
Efficacy and tolerability of treatment with the new direct acting antivirals (DAAs) in thalassemic patients with chronic Hepatitis 1.940
Is the Inversion in the Trend of the Lethality of the COVID-19 in the Two Hemispheres due to the Difference in Seasons and Weather? 1.940
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D 1.839
Long-latency potential study in minimal hepatic hencephalopaty 1.794
Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in co-infected HIV-HCV patients treated with the new direct acting antivirals (DAAs) 1.778
null 1.742
The Effect of Exposure to SARS-CoV-2 Vaccination and Infection on Humoral and Cellular Immunity in a Cohort of Patients with Immune-Mediated Diseases: A Pilot Study 1.729
Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful? 1.721
The climate in the European Union and the enlarged European Region is a determinant of the COVID-19 case fatality ratio 1.715
null 1.710
SAFETY AND EFFICACY OF PEG-IFN alpha 2a AND RIBAVIRIN FOR TREATMENT OF HEPATITIS C IN SARDINIAN ADULT PATIENTS WITH THALASSEMIA MAJOR: A SINGLE CENTRE REAL LIFE EXPERIENCE 1.676
null 1.666
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 1.666
Evolution of the viral quasispecies tracked by sequence analysis during interferon treatment of chronic hepatitis C. 1.664
Multidimensional geriatric assessment in elderly HIV patients 1.656
null 1.610
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 1.570
The COVID-19 incidence in Italian regions correlates with low temperature, mobility and PM10 pollution but lethality only with low temperature 1.558
Orthotopic liver transplantation in neurological Wilson desease: case report 1.549
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 1.538
HepaDisk – A new quality of life questionnaire for HCV patients 1.527
EVALUATION OF MILD COGNITIVE DYSFUNCTION BY MONTREAL COGNITIVE ASSESSMENT TEST IN PATIENTS WITH CHRONIC HCV INFECTION 1.525
Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection 1.476
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort 1.463
Individualized long-term treatment of chronic hepatitis C with interferon alpha (IFN alpha)-2a. 1.453
null 1.424
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 1.396
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 1.382
Evolution of the HCV quasispecies and pattern of response to interferon therapy in patients with chronic hepatitis C 1.379
Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination 1.373
Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination 1.371
Real-world data on the treatment of primary biliary cholangitis with obeticholic acid in Italy: the CLEO-AIGO OCA cohort. 1.335
Management of primary biliary cholangitis in the pre-obeticholic acid era, and the rate of non-response to ursodeoxycholic acid (UDCA), in a large real-world cohort of PBC patients in Italy: The CLEO-AIGO database 1.332
Optimization of hepatitis C virus screening strategies by birth cohort in Italy 1.315
Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy 1.295
Can antiretroviral therapy modify the clinical course of HDV infection in HIV positive patients? 1.292
A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population 1.280
La quasispecie del virus dell’epatite C: implicazioni biologiche e cliniche 1.277
null 1.208
Forecasting liver disease burden 1.202
Predictive Factors for Liver Disease Progression Following the Direct Acting Antivirals Induced Sustained Virological Response: Data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) Cohort 1.192
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 1.144
A review of the main genetic factors influencing the course of COVID-19 in Sardinia: the role of human leukocyte antigen-G 1.143
Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy 1.139
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 1.127
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 1.123
Epidemiological and Economic Evaluations According to Daa Treatment Access in Italy Based on Real Life Piter Cohort Data 1.122
Risultati preliminari di uno studio di fase II con Sorafenib in pazienti anziani affetti da epatocarcinoma 1.118
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? 1.096
Previous functional social and behavioral rhythms affect resilience to COVID-19-related stress among old adults 1.093
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An Innovate study protocol 1.083
Long term effectiveness of DAA therapy in patients with chronic HCV and Mixed Cryoglobulinemic Syndrome 1.082
Optimization of Hepatitis C Virus screening strategies by birth cohort in Italy 1.054
Clinical characterization and economic impact evaluation of antiHCV DAA treatment failure:real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) 1.052
L'approccio basato sui casi per la diagnosi di malattie epatiche 1.046
Combined Salivary Proteome Profiling and Machine Learning Analysis Provides Insight into Molecular Signature for Autoimmune Liver Diseases Classification 1.013
Forecasting Hepatitis C liver disease burden based on real life data. Does the hidden iceberg matter to reach the World Health Organization elimination goals? 1.013
Distribution of IL28B polymorphism in a cohort of Italians and immigrants with HCV infection: association with viraemia, stage of fibrosis and response to treatment 1.008
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 996
Mixed cryoglobulinemia: an important but frequently unrecognized and underestimated HCV-related condition in the real life practice 996
Solid Organ Transplantation During COVID-19 Pandemic: An International Web-based Survey on Resources’ Allocation 973
STUDY OF VALIDATION OF ANGIOGENESIS POLYMORPHISMS IN HCC PATIENTS TREATEDWITH SORAFENIB. INNOVATE STUDY 969
Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals? 957
Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study 957
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV Gruppo 956
Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study 948
COVID-19 Vaccine Hesitancy among Italian Healthcare Workers: Latent Profiles and Their Relationships to Predictors and Outcome 933
Iron concentration and distribution in the newborn liver 915
Modeling cost-effectiveness and health gains of a “universal“ versus “prioritized“ hepatitis C virus treatment policy in a real-life cohort 911
The double-sided of human leukocyte antigen-G molecules in type 1 autoimmune hepatitis 905
Covid-19 vaccines work but other factors play a relevant role: a data analysis on spread and mortality in 24 countries 905
HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study 896
The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis 896
Totale 185.109
Salva come PNG Salva come JPEG
Categoria #
all - tutte 347.031
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 347.031
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20229.160 0 0 0 0 958 985 865 724 1.097 996 1.535 2.000
2022/202319.438 2.076 2.643 2.596 1.408 1.692 1.926 893 1.655 1.133 1.086 1.435 895
2023/202422.027 1.023 1.137 1.230 1.719 2.007 3.667 3.457 1.523 1.022 1.463 1.747 2.032
2024/202558.197 7.306 29.122 5.040 4.491 2.321 2.498 3.731 305 643 1.622 494 624
2025/202614.586 1.015 933 1.898 1.238 1.113 1.207 2.685 723 1.127 1.392 922 333
2026/20275.212 682 876 1.395 2.013 246 0 0 0 0 0 0 0
Totale 247.395